Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

NCT03467113 is registered in ClinicalTrials.gov with Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. as lead sponsor.

NCT NCT03467113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03467113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 19, 2018
Completion date
June 24, 2020
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dravet syndrome, lennox gastaut syndrome